Jaguar HealthJAGX +1.33%22 Gross Margin % is 94.28% as of Mar. 2026, which is 43% above its 10-year median of 66.13. GuruFocus rates JAGX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 733 Biotechnology companies, Jaguar Health ranks better than 77.9% on this metric.
The historical rank and industry rank for Jaguar Health's Gross Margin % or its related term are showing as below:
JAGX'
s Gross Margin % Range Over the Past 10 Years
Min: 33.92 Med: 66.13 Max: 85.05
Current: 85.05
During the past 13 years, the highestGross Margin % of Jaguar Health was 85.05%. The lowest was 33.92%. And the median was 66.13%.
JAGX's Gross Margin % is ranked better than 77.9% of 733
companies
in the Biotechnology industry
Industry Median: 60.9
vs JAGX: 85.05
Jaguar Health had a gross margin of 94.28% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Jaguar Health was 5.50% per year.
Jaguar Health (NAS:JAGX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Jaguar Health had a gross margin of 94.28% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Jaguar Health Gross Margin % Related Terms
Jaguar Health Gross Margin % Historical Data
* Premium members only.
The historical data trend for Jaguar Health's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JAGX vs MBRX, BCDA, GRTX: Gross Margin % Comparison
For the Biotechnology subindustry, Jaguar Health's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Jaguar Health's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Jaguar Health (JAGX) has a Gross Margin % of 94.28% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Jaguar Health and its competitors. This is 43% above median its historical median of 66.13. Over the past decade, Jaguar Health's Gross Margin % has ranged from 33.92 to 85.05. According to the industry distribution chart, Jaguar Health ranks #162 out of 733 companies in the Biotechnology industry, placing it in the top 22.1%.
Is Jaguar Health's Gross Margin % too high?
Jaguar Health's current Gross Margin % of 94.28% is 43% above median its 10-year median of 66.13. Over the past 10 years, this metric has ranged from a low of 33.92 to a high of 85.05. The Biotechnology industry median Gross Margin % is 60.90. Jaguar Health's value of 94.28% is 54.8% above this industry median. Based on the distribution chart, Jaguar Health ranks #162 out of 733 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jaguar Health has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's Gross Margin % compare to MBRX and BCDA?
According to the Biotechnology industry distribution chart, Jaguar Health ranks #162 out of 733 companies for Gross Margin %. This places Jaguar Health in the top 22% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.90. Jaguar Health's value of 94.28% is 54.8% above this benchmark. Historically, Jaguar Health's own Gross Margin % has ranged from 33.92 to 85.05 over the past decade. While the company's 10-year median is 66.13 vs. the industry median of 60.90, Jaguar Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jaguar Health's current Gross Margin % of 94.28% is 54.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Jaguar Health and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jaguar Health's current Gross Margin % is 94.28%, which is 43% above median its own 10-year median of 66.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Jaguar Health (JAGX) has a current Gross Margin % of 94.28%. The current Gross Margin % is 94.28%, which is 43% above median its 10-year median of 66.13 and 54.8% above the Biotechnology industry median of 60.90. Jaguar Health's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Jaguar Health (JAGX), the current Gross Margin % is 94.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
22GF Score
Get the complete analysis for JAGX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAGX has been successfully added to your 
